Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study

Darcis, Gilles; Bouquegneau, Antoine; Maes, Nathalie; Thys, Marie; Henket, Monique; Labye, Florence; Rousseau, Anne-Françoise; Canivet, Perrine; Desir, Colin; Calmès, Doriane; Schils, Raphaël; Worm, Sophie De; Léonard, Philippe; Meunier, Paul; Moutschen, Michel; Louis, Renaud; Guiot, Julien

doi:10.1016/j.ijid.2021.07.016

Cited by 46 publications

(50 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 193 studies under full-text review, 153 studies were excluded. Eventually, 40 studies were included in this meta-analysis based on the inclusion criteria [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ]. The literature retrieval flow chart is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis

Deng

Liu

et al. 2022

IJERPH

View full text Add to dashboard Cite

We aimed to review the data available to evaluate the long-term consequences of coronavirus disease 2019 (COVID-19) at 6 months and above. We searched relevant observational cohort studies up to 9 February 2022 in Pubmed, Embase, and Web of Science. Random-effects inverse-variance models were used to evaluate the Pooled Prevalence (PP) and its 95% confidence interval (CI) of long-term consequences. The Newcastle–Ottawa quality assessment scale was used to assess the quality of the included cohort studies. A total of 40 studies involving 10,945 cases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection were included. Of the patients, 63.87% had at least one consequence at the 6 month follow-up, which decreased to 58.89% at 12 months. The most common symptoms were fatigue or muscle weakness (PP 6–12 m = 54.21%, PP ≥ 12 m = 34.22%) and mild dyspnea (Modified Medical Research Council Dyspnea Scale, mMRC = 0, PP 6–12 m = 74.60%, PP ≥ 12 m = 80.64%). Abnormal computerized tomography (CT; PP 6–12 m = 55.68%, PP ≥ 12 m = 43.76%) and lung diffuse function impairment, i.e., a carbon monoxide diffusing capacity (DLCO) of < 80% were common (PP 6–12 m = 49.10%, PP ≥ 12 m = 31.80%). Anxiety and depression (PP 6–12 m = 33.49%, PP ≥ 12 m = 35.40%) and pain or discomfort (PP 6–12 m = 33.26%, PP ≥ 12 m = 35.31%) were the most common problems that affected patients’ quality of life. Our findings suggest a significant long-term impact on health and quality of life due to COVID-19, and as waves of ASRS-CoV-2 infections emerge, the long-term effects of COVID-19 will not only increase the difficulty of care for COVID-19 survivors and the setting of public health policy but also might lead to another public health crisis following the current pandemic, which would also increase the global long-term burden of disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis

Deng

Liu

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…[ 3 , 22 ] However, in these studies, as in our cohort, a significant improvement in DLCO was observed after six months. [ 3 , 23 , 24 ] Zhang et al reported a 32% reduction in DLCO after severe COVID-19 after eight months. In their cohort, 30% of patients had interstitial lung abnormalities, with ground glass being the most frequent (50%), followed by irregular lines.…”

Section: Discussionmentioning

confidence: 99%

Lung function six months after severe COVID-19: Does time, in fact, heal all wounds?

Bretas

Leite

Mancuzo

et al. 2022

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

“…SARS-CoV-2 infection responsible for Coronavirus disease 2019 (COVID-19) is associated with a variability in clinical presentation and pathologic features, such as a minority of patients rapidly progressing to severe life-threatening respiratory failure requiring mechanical ventilation [ 1 ]. A proportion of COVID-19 patients suffer from post-acute sequelae, experiencing complications affecting different organs (a condition defined as “long COVID-19”, “long-haul” syndrome, or “post-acute COVID syndrome” (PACS) [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. Most common symptoms often persisting for several weeks or months include systemic manifestations (fatigue, asthenia, poor concentration, wandering fever), symptoms and signs of pulmonary functional impairment (dyspnea, cough, reduced DLCO—diffusing capacity of the lungs for carbon monoxide), neuropsychiatric manifestations (sleep disturbances, cognitive dysfunction, depression, mood changes, anxiety, headache, taste, and/or smell loss), cardiac manifestations (chest pain, palpitations, tachycardia, dysrhytmias), as well as a variety of muscle-skeletal, renal, dermatological, and gastrointestinal manifestations [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia

et al. 2022

View full text Add to dashboard Cite

Despite intense investigation, the pathogenesis of COVID-19 and the newly defined long COVID-19 syndrome are not fully understood. Increasing evidence has been provided of metabolic alterations characterizing this group of disorders, with particular relevance of an activated tryptophan/kynurenine pathway as described in this review. Recent histological studies have documented that, in COVID-19 patients, indoleamine 2,3-dioxygenase (IDO) enzymes are differentially expressed in the pulmonary blood vessels, i.e., IDO1 prevails in early/mild pneumonia and in lung tissues from patients suffering from long COVID-19, whereas IDO2 is predominant in severe/fatal cases. We hypothesize that IDO1 is necessary for a correct control of the vascular tone of pulmonary vessels, and its deficiency in COVID-19 might be related to the syndrome’s evolution toward vascular dysfunction. The complexity of this scenario is discussed in light of possible therapeutic manipulations of the tryptophan/kynurenine pathway in COVID-19 and post-acute COVID-19 syndromes.

show abstract

Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study

Abstract: Long-term clinical follow up of patients suffering from moderate to severe COVID-19 infection: A monocentric prospective observational cohort study,

Cited by 46 publications

References 46 publications

Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis

Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis

Lung function six months after severe COVID-19: Does time, in fact, heal all wounds?

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia

Contact Info

Product

Resources

About